UOC Oncologia, ULSS 1 Dolomiti, Belluno Medical Hospital "San Martino", Viale Europa 22, 32100 Belluno, Italy.
Bayer Spa, Viale Certosa 210, 201156 Milan, Italy.
Int J Mol Sci. 2017 Dec 28;19(1):74. doi: 10.3390/ijms19010074.
The skeleton is the target tissue for many types of tumors, and, recently, the survival of patients with prostate cancer metastasis has been increased using α-emitting drugs known as targeted α therapies. The use of α-radiopharmaceuticals in medicine was hypothesized at the beginning of the nineteenth century after the observation that α-radionuclides were associated with high cell-killing energy and low tissue penetration in healthy tissues. In the prostate cancer (PC) scenario, current research suggests that this class of radiopharmaceuticals has limited toxicity, and that the mechanism of action does not overlap with pre-existing drugs, allowing us to extend therapeutic armaments and address medical oncology towards personalized and precision medicine. Ongoing studies may extend these benefits also to bone metastases deriving from other neoplasms. The aim of this review is to summarize the current research on targeted α therapies and try to identify the right patient to be treated in the right time in order to integrate in these medications in the every-day clinical practice.
骨骼是许多类型肿瘤的靶组织，最近，使用称为靶向 α 疗法的 α 发射药物已提高了患有前列腺癌转移的患者的生存率。在 19 世纪初，人们观察到 α 放射性核素与健康组织中高细胞杀伤能量和低组织穿透力相关，从而假设了 α 放射性药物在医学中的应用。在前列腺癌 (PC) 情况下，目前的研究表明，这类放射性药物的毒性有限，作用机制与现有药物不重叠，使我们能够扩大治疗手段，并将肿瘤医学转向个性化和精准医学。正在进行的研究可能会将这些益处也扩展到源自其他肿瘤的骨转移。本文综述的目的是总结目前关于靶向 α 疗法的研究，并尝试确定合适的患者，以便在合适的时间进行治疗，从而将这些药物整合到日常临床实践中。
